3twd

Publication Abstract from PubMed

GlmU is a bifunctional enzyme that is essential for bacterial growth, converting D-glucosamine-1-phosphate into UDP-GlcNAc via acetylation and subsequent uridyl transfer. A biochemical screen of AstraZeneca's compound library using GlmU of Escherichia coli identified novel sulfonamide inhibitors of the acetyl transferase reaction. Steady state kinetics, ligand-observe NMR, isothermal titration calorimetry and X-ray crystallography showed that the inhibitors were competitive with acetyl-CoA substrate. Iterative chemistry efforts improved biochemical potency against Gram-negative isozymes 300-fold and afforded antimicrobial activity against a strain of Haemophilus influenzae lacking its major efflux pump. Inhibition of precursor incorporation into bacterial macromolecules was consistent with the antimicrobial activity being caused by disruption of peptidoglycan and fatty acid biosyntheses. Isolation and characterization of two different resistant mutant strains identified the GlmU acetyl transferase domain as the molecular target. These data, along with X-ray co-crystal structures, confirmed the binding mode of the inhibitors and explained their relative lack of potency against Gram-positive GlmU isozymes. This is the first example of antimicrobial compounds mediating their growth inhibitory effects specifically via GlmU.

In Vitro validation of the acetyl transferase activity of GlmU as an antibacterial target in Haemophilus influenzae.,Buurman ET, Andrews B, Gao N, Hu J, Keating TA, Lahiri S, Otterbein LR, Patten AD, Stokes SS, Shapiro AB J Biol Chem. 2011 Oct 7. PMID:21984832^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.